Trasdermal buprenorphine in clinical practice: perception of patients with moderate chronic pain

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-14005332

Enrollment

Unknown

Registered

2014-09-13

Start date

2014-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate chronic pain

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: patients that first time receive transdermal buprenorphine with moderate non-malignant chronic pain; older than 18 years; duration of pain more than 1 month; NRS pionts more than 4; patients or their family members can accomplish the pain assessment.

Exclusion criteria

Exclusion criteria: Exclusion criteria were severe viscera disease neurological or psychiatric diseases which could interfere with the subjects completion of the intended observation period, drug or alcohol abuse, a history of hypersensitivity to buprenorphine or to patch excipients, and other contraindications listed in the summary of product characteristics.

Design outcomes

Primary

Measure	Time frame
NRS pain score;quality of life;	—

Contacts

Public ContactYan Min

yanm@z2hospital.com+86 13757118632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026